Glyscend study reveals metabolic benefits of its oral polymer-based duodenal exclusion therapyGlyscend has presented data from a study of its proprietary oral polymer duodenal exclusion therapy, at the American Diabetes Association...
Standardisation of OAGB is key to reducing surgical errors and ensuring consistent patient outcomes2 days ago